id	等位基因	注释文本
705	*3	Patients with CYP2C9*3 in combination with a normal function allele, a decreased function allele, or a no function allele may have increased risk of over-anticoagulation when treated with acenocoumarol as compared to patients with two normal function alleles. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.
704	*2	Patients with CYP2C9*2 in combination with another normal function allele, a decreased function allele, or a no function allele may have increased risk of over-anticoagulation when treated with acenocoumarol as compared to patients with two normal function alleles. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.
703	*1	Patients carrying CYP2C9*1 allele in combination with another normal function allele may have decreased risk of over-anticoagulation when treated with acenocoumarol as compared to patients carrying at least one copy of a decreased function or no function allele. However, conflicting evidence has been reported. This drug-variant pair has been assigned a 鈥渘o recommendation鈥?by DPWG, as it was determined to be not clinically actionable.Other genetic and clinical factors may also influence the toxicity to acenocoumarol.

id	证据的ID	总结
712	1444707520	CYP2C9 3/3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
711	1444707467	CYP2C9 1/3 + 3/3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
710	1444707455	CYP2C9 3/3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 1/1.
709	1444707371	CYP2C9 3/3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
708	1444707358	CYP2C9 1/2 + 2/2 are not associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
707	1444707332	CYP2C9 1/3 + 3/3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
706	1444707293	CYP2C9 1/2 + 2/2 + 2/3 + 1/3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
705	1444707009	CYP2C9 2/2 + 2/3 + 3/3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
704	1444706597	CYP2C9 1/2 + 2/2 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
703	1444706561	CYP2C9 1/3 + 3/3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
702	1444705909	CYP2C9 1/3 + 3/3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
701	1444705857	CYP2C9 1/3 + 3/3 + 2/3 are associated with increased likelihood of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
700	1184996754	CYP2C9 1/2 + 2/2 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
699	1184996740	CYP2C9 1/3 + 3/3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/1.
698	982031260	CYP2C9 3 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 1/*1.
697	982031251	CYP2C9 2 is associated with increased risk of overanticoagulation when treated with acenocoumarol as compared to CYP2C9 1/*1.
696	655388486	Genotype CC is associated with increased risk of overanticoagulation when treated with acenocoumarol.
270	1449188485	CYP2C9 3 is associated with increased likelihood of Blood Coagulation Disorders when treated with acenocoumarol in people with Atrial Fibrillation, Atrial Flutter or Venous Thrombosis as compared to CYP2C9 1.
269	1447678839	CYP2C9 3 is associated with increased risk of over-anticoagulation when treated with acenocoumarol as compared to CYP2C9 1/*1.
268	1444708161	CYP2C9 1/3 + 3/3 are associated with increased risk of over-anticoagulation when treated with acenocoumarol or warfarin as compared to CYP2C9 1/1.

id	类型	评论
962	Update	Added sentence about DPWG 'no recommendation' to phenotype descriptions
961	Update	CA score added as part of scoring system release. LOE assigned following curator review.
960	Update	updated text
959	Update	Reviewed.
958	Update
957	Create

最新招商产品更多>>